Clinical trial NCT03311789: Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Official title: A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Biliary Tract Cancer
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2017-10-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Enrolled patients will be treated with PD-1 inhibitor in combination with gemcitabine/cisplatin chemotherapy.
Primary purpose: TREATMENT

Brief summary: This is a single-arm, phase I/II trial in biliary tract cancer (BTC) patients. The purpose of this trial is to evaluate the safety and effect of PD-1 inhibitor in combination with gemcitabine/cisplatin chemotherapy in patients with advanced unresectable or metastatic BTCs.

The primary objective: 6-month progression free survival (PFS). The second objectives: objective clinical response(according to RECIST version 1.1), safety, symptom control and quality of life (QoL) (according to EORTC QoL C30 and BIL 21), overall survival. The exploratory objectives: assessment of immunological response (cytokines, lymphocyte phenotype, immunoglobulins), and evaluation of pathological, immunological and clinical predictive factors for response/toxicity.


Eligibility criteria: Inclusion Criteria:

* Age≥18 years with estimated life expectancy \>3 months.
* Histopathological/cytological diagnosis of unresectable or recurrent / metastatic biliary tract carcinoma (intra-hepatic, extrahepatic or gall bladder) and had at least one measurable disease (≥1cm) by CT or MRI.
* Patients should provide samples of tumor tissue biopsied or resected no more than 3 months before enrollment and be willing to accept biopsy in the process of the study.
* Patients may have received prior radiotherapy,chemotherapy,or other local ablative therapies, which completed ≥ 4 weeks prior to registration AND patient has recovered to \<= grade 1 toxicity.
* ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.
* Adequate organ and marrow function obtained ≤ 2 weeks prior to registration as defined below:

leukocytes greater than or equal to 3.0 x 10\^9/L absolute neutrophil count greater than or equal to 1.0 x 10\^9/L platelets greater than or equal to 100 x 10\^9/L hemoglobin greater than or equal to 90 g/L total bilirubin less than or equal to 2 xULN serum albumin should be no less than 25g/L ALT or AST less than 2 xULN serum creatinine less than 1.5 x ULN

* Ability to understand and willingness to sign a written informed consent document.
* women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and up to 120 days after the last dose of the drug.

Exclusion Criteria:

* Active, known or suspected autoimmune diseases.
* Known brain metastases or active central nervous system (CNS). If patients with CNS metastases were treated with radiotherapy for at least 3 months prior to enrollment and have no central nervous symptoms and are off corticosteroids, they will be eligible but will need a Brain MRI prior to enrollment.
* Participants are being treated with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
* Prior therapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody (including ipilimumab or any other antibody specifically targeting T-cell costimulation or checkpoint pathways).
* History of severe hypersensitive reactions to other monoclonal antibodies.
* History of allergy or intolerance to study drug components.
* Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
* History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function.
* Uncontrolled intercurrent illness including ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
* History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
* Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented.
* Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\].
* Vaccination within 30 days of study enrollment.
* Active bleeding or known hemorrhagic tendency.
* Patients with unhealed surgical wounds for more than 30 days.
* Being participating any other trials or withdraw within 4 weeks.

Primary outcomes:
measure: The percentage of patients alive and without progression at 6 months
timeFrame: 6 months
Secondary outcomes:
measure: The percentage of patients that respond to combination treatment
timeFrame: Enrolled patients will be followed until death, withdrawal from study, or until 2 years.
measure: Median overall survival time
timeFrame: Patients will be followed until death, withdrawal from study, or until 2 years.
measure: List of adverse event frequency and grade
timeFrame: Up to 120 days after last administration of PD-1 inhibitor
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Biotherapeutic, Chinese PLA General Hospital
Study officials:
affiliation: Department of Biotherapeutic, Chinese PLA General Hospital
name: Weidong Han, Ph.D
role: STUDY_DIRECTOR
References:
citation: Feng K, Liu Y, Zhao Y, Yang Q, Dong L, Liu J, Li X, Zhao Z, Mei Q, Han W. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer. 2020 Jun;8(1):e000367. doi: 10.1136/jitc-2019-000367.